The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)

This double-blind, randomized, placebo-controlled, parallel-group laboratory trial (n=63) conducted by Yale University aims to determine the effects of DMT (14-21mg/70kg/min) infusions, in conjunction with psychotherapy, on Alcohol Use Disorder (AUD).

The study hypothesizes that compared to the control group receiving a specific infusion plus psychotherapy, a single dose of DMT (plus psychotherapy) in individuals with AUD will be safe, well-tolerated, and will reduce alcohol consumption measured in the laboratory the day after and over the following 8 weeks.

Eligible participants, aged 21-65, must have a DSM-5 diagnosis of AUD and be medically healthy, capable of providing consent. Exclusion criteria include unstable medical conditions.

The trial will involve three groups: Group 1 receiving a bolus of 0.3mg/kg/min DMT infusion, Group 2 receiving a bolus of 0.2 mg/kg/min DMT infusion, and Group 3 receiving a placebo infusion. These infusions will be administered over specific timeframes.

Primary outcome measures include the safety and tolerability of DMT and its effects on alcohol consumption, while secondary outcomes include assessing the relationship between DMT effects and alcohol consumption, changes in personality traits, and the intensity of subjective psychedelic experience.

The study is expected to start on March 17, 2024, with an estimated completion date of September 30, 2025, and will be conducted at Connecticut Mental Health Center, New Haven, Connecticut, USA.

Topic Alcohol Use Disorder Addiction
Compound DMT Placebo
Country United States of America
Visit trial
Status Not yet recruiting
Results Published No
Start date 17 March 2024
End date 30 September 2025
Phase Phase I
Design Blinded
Type Interventional
Generation First
Participants 63
Sex All
Age 21- 65
Therapy Yes

Trial Details

This proposed study is a double-blind, randomized, placebo-controlled, parallel-group, laboratory study to determine the effects of DMT, plus psychotherapy, on Alcohol Use Disorder.

NCT Number NCT06070649

Sponsors & Collaborators

Yale University
The Yale Psychedelic Science Group was established in 2016.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.